Search: onr:"swepub:oai:DiVA.org:uu-205404" >
A Combination Regim...
A Combination Regimen of Bortezomib, Cyclophosphamide and Betamethasone Gives Quicker, Better and More Durable Response than VAD/CyBet Regimens : Results from a Swedish Retrospective Analysis
-
- Uttervall, Katarina (author)
- Karolinska Institutet
-
Admasie, Johannes (author)
-
- Alici, Evren (author)
- Karolinska Institutet
-
show more...
-
- Lund, Johan (author)
- Karolinska Institutet
-
Liwing, Johan (author)
-
Aschan, Johan (author)
-
Barendse, Mirjam (author)
-
- Deneberg, Stefan (author)
- Karolinska Institutet
-
Mellqvist, Ulf-Henrik (author)
-
- Carlson, Kristina (author)
- Uppsala universitet,Hematologi och immunologi,Hematologi
-
- Nahi, Hareth (author)
- Karolinska Institutet
-
show less...
-
(creator_code:org_t)
- 2013-01-25
- 2013
- English.
-
In: Acta Haematologica. - : S. Karger AG. - 0001-5792 .- 1421-9662. ; 130:1, s. 7-15
- Related links:
-
https://www.karger.c...
-
show more...
-
https://urn.kb.se/re...
-
https://doi.org/10.1...
-
http://kipublication...
-
show less...
Abstract
Subject headings
Close
- Background: Induction therapy for multiple myeloma (MM) and remission status before high-dose treatment (HDT) have been shown to be prognostic factors for survival outcome, although the optimal induction therapy is yet to be defined. Methods: We conducted a retrospective analysis of the impact of induction therapy on survival outcome before and after HDT in MM patients. The study included 236 consecutive patients who underwent HDT. Results: One hundred and forty-two patients (62%) were treated with vincristine, doxorubicin and dexamethasone (VAD) or cyclophosphamide and betamethasone (CyBet) and 94 (38%) were treated with bortezomib, cyclophosphamide and betamethasone (VCB) as induction. Time to first and time to best response was faster in the VCB group than in the VAD/CyBet group, with 42 versus 75 (p < 0.001) and 54 versus 88 days (p < 0.001), respectively. After induction therapy, 49% of the patients in the VCB group and 38% in the VAD/CyBet group achieved a very good partial response or better. Multivariate analysis revealed younger age, lower International Staging System stage and induction treatment with VCB as variables associated with favourable time to progression. Conclusions:Outcome measured as response and time to progression before and after HDT in MM differs depending on type of induction treatment and suggests that VCB is a highly effective induction regimen that confers a post-HDT advantage.
Subject headings
- MEDICIN OCH HÄLSOVETENSKAP -- Klinisk medicin -- Cancer och onkologi (hsv//swe)
- MEDICAL AND HEALTH SCIENCES -- Clinical Medicine -- Cancer and Oncology (hsv//eng)
- MEDICIN OCH HÄLSOVETENSKAP -- Medicinska och farmaceutiska grundvetenskaper -- Farmakologi och toxikologi (hsv//swe)
- MEDICAL AND HEALTH SCIENCES -- Basic Medicine -- Pharmacology and Toxicology (hsv//eng)
Keyword
- High-dose therapy
- Multiple myeloma
- Vincristine
- doxorubicin and dexamethasone regimen
Publication and Content Type
- ref (subject category)
- art (subject category)
Find in a library
To the university's database
- By the author/editor
-
Uttervall, Katar ...
-
Admasie, Johanne ...
-
Alici, Evren
-
Lund, Johan
-
Liwing, Johan
-
Aschan, Johan
-
show more...
-
Barendse, Mirjam
-
Deneberg, Stefan
-
Mellqvist, Ulf-H ...
-
Carlson, Kristin ...
-
Nahi, Hareth
-
show less...
- About the subject
-
- MEDICAL AND HEALTH SCIENCES
-
MEDICAL AND HEAL ...
-
and Clinical Medicin ...
-
and Cancer and Oncol ...
-
- MEDICAL AND HEALTH SCIENCES
-
MEDICAL AND HEAL ...
-
and Basic Medicine
-
and Pharmacology and ...
- Articles in the publication
-
Acta Haematologi ...
- By the university
-
Uppsala University
-
Karolinska Institutet